Gut Lactobacillus protects against the progression of renal damage by modulating the gut environment in rats
- PMID: 26487672
- DOI: 10.1093/ndt/gfv353
Gut Lactobacillus protects against the progression of renal damage by modulating the gut environment in rats
Abstract
Background: The role of gut microbiota in the progression of chronic kidney disease (CKD) has not been fully elucidated.
Methods: Renal failure was induced in 6-week-old spontaneously hypertensive rats by 5/6 nephrectomy (Nx). We analyzed the gut microbiota population to identify the relevant species potentially involved in inducing renal damage. Human colon Caco-2 cells were used to delineate the mechanism involved in the molecular changes in the gut of Nx rats.
Results: Nx rats showed an increase in Bacteroides (Bact) and a decrease in Lactobacillus (Lact) species compared with sham-operated rats. Lact, but not Bact, populations were significantly associated with urinary protein excretion. Treatment of Nx rats with 1 × 10(10) CFU/kg/day Lact ameliorated increased urinary protein excretion and higher serum levels of the uremic toxins, indoxyl sulfate and p-cresyl sulfate, and serum urea nitrogen levels. Lact also attenuated systemic inflammation in Nx rats, as evaluated by serum lipopolysaccharide, interleukin-6 and C-reactive protein levels. Histologically, renal sclerosis in Nx rats was restored by Lact treatment. A reduction in the expression of tight junction proteins and the Toll-like receptor 2 (TLR2), a putative Lact receptor, in the colons of Nx rats were mitigated by Lact. Treatment of Caco-2 cells with indole downregulated tight junction protein expression, which was abolished by exposure to Lact. The effects of Lact were reversed by treatment with OxPAPC, a TLR inhibitor. Similarly, the increase in the permeability of the Caco-2 cell monolayer was reversed by the administration of Lact. Lact upregulated TLR2 expression in Caco-2 cells. Lact also attenuated the increase in serum indoxyl sulfate and urea levels and urinary protein excretion in Nx rats even in the pseudogerm-free environment.
Conclusions: Lact supplementation mitigated the systemic inflammation and proteinuria associated with renal failure, suggesting that in the gut microbiota, Lact plays a protective role against the progression of CKD.
Keywords: Toll-like receptor; chronic kidney disease; gut microbiota; protein bound uremic retention solutes; tight junction.
© The Author 2015. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
Similar articles
-
Oral adsorbent AST-120 ameliorates gut environment and protects against the progression of renal impairment in CKD rats.Clin Exp Nephrol. 2018 Oct;22(5):1069-1078. doi: 10.1007/s10157-018-1577-z. Epub 2018 Apr 19. Clin Exp Nephrol. 2018. PMID: 29675795 Free PMC article.
-
Sodium butyrate ameliorates insulin resistance and renal failure in CKD rats by modulating intestinal permeability and mucin expression.Nephrol Dial Transplant. 2019 May 1;34(5):783-794. doi: 10.1093/ndt/gfy238. Nephrol Dial Transplant. 2019. PMID: 30085297 Free PMC article.
-
Disorder of gut amino acids metabolism during CKD progression is related with gut microbiota dysbiosis and metagenome change.J Pharm Biomed Anal. 2018 Feb 5;149:425-435. doi: 10.1016/j.jpba.2017.11.040. Epub 2017 Nov 15. J Pharm Biomed Anal. 2018. PMID: 29169110
-
[Pathomechanism and treatment of gut microbiota dysbiosis in chronic kidney disease and interventional effects of Chinese herbal medicine].Zhongguo Zhong Yao Za Zhi. 2017 Jul;42(13):2425-2432. doi: 10.19540/j.cnki.cjcmm.20170609.014. Zhongguo Zhong Yao Za Zhi. 2017. PMID: 28840678 Review. Chinese.
-
Impact of Altered Intestinal Microbiota on Chronic Kidney Disease Progression.Toxins (Basel). 2018 Jul 19;10(7):300. doi: 10.3390/toxins10070300. Toxins (Basel). 2018. PMID: 30029499 Free PMC article. Review.
Cited by
-
Fucoxanthin Ameliorates Kidney Injury by CCl4-Induced via Inhibiting Oxidative Stress, Suppressing Ferroptosis, and Modulating Gut Microbiota.ACS Omega. 2025 Feb 14;10(7):7407-7421. doi: 10.1021/acsomega.4c11437. eCollection 2025 Feb 25. ACS Omega. 2025. PMID: 40028144 Free PMC article.
-
Uric Acid and Atherosclerosis in Patients with Chronic Kidney Disease: Recent Progress, Mechanisms, and Prospect.Kidney Dis (Basel). 2025 Mar 3;11(1):112-127. doi: 10.1159/000543781. eCollection 2025 Jan-Dec. Kidney Dis (Basel). 2025. PMID: 40124130 Free PMC article. Review.
-
2bRAD-M reveals circulating microbiome in chronic antibody-mediated rejection (CAMR) and IgA nephropathy (IgAN) after kidney transplantation.BMC Microbiol. 2025 Jul 31;25(1):468. doi: 10.1186/s12866-025-04103-3. BMC Microbiol. 2025. PMID: 40745634 Free PMC article.
-
Gut microbiota-targeted therapies in pediatric chronic kidney disease: gaps and opportunities.Pediatr Nephrol. 2025 May 1. doi: 10.1007/s00467-025-06789-z. Online ahead of print. Pediatr Nephrol. 2025. PMID: 40307477 Review.
-
Diet and Proteinuria: State of Art.Int J Mol Sci. 2022 Dec 20;24(1):44. doi: 10.3390/ijms24010044. Int J Mol Sci. 2022. PMID: 36613485 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials